Myeloid neoplasms with eosinophilia and abnormal PDGFRA/B: report of three cases and review of literature / 白血病·淋巴瘤

Objective To investigate clinical and hematological features of myeloid neoplasms with eosinophilia and abnormal PDGFRA/B and the effect of imatinib. Methods The data of three eosinophilia patients with abnormal PDGFRA/B fusion gene in Changhai Hospital, the Second Military Medical University and 22 Chinese cases reported in Chinese medical journals were analyzed. Thirty-one cases of idiopathic hypereosinophilic syndrome from Changhai Hospital, the Second Military Medical University were used as the controls. Results Compared with idiopathic hypereosinophilic syndrome, no differences were found in age, percentage of bone marrow eosinophils and counts of platelets in peripheral blood in myeloid neoplasms with eosinophilia and abnormal PDGFRA/B (all P ＞0.05), but statistical differences were found in gender (χ2＝5.080, P ＝ 0.016), peripheral blood white blood cell count (t ＝ 4.908, P ＝ 0.001), eosinophilic granulocyte absolute value (χ2＝ 17.230, P ＝ 0.001) and hemoglobin concentration (t ＝ 2.770, P ＝ 0.013). The median follow-up time was 17 months (3-108 months) in 24 myeloid neoplasms patients with eosinophilia and abnormal PDGFRA/B from Chinese report. Complete hematopoietic remission (CHR) rate was 91.7 % (22/24) after the treatment of imatinib. The total complete molecular remission (CMR) rate was 75.0 % (18/24). The median time of remission was 3 months (1-8 months). CMR in patients with PDGFRA and with PDGFRB was 76.5 % (13/17) and 85.7 % (6/7), respectively. Only one patient (4.2 %) died of disease relapse. Conclusion Imatinib has a favorable effect on myeloid neoplasms with eosinophilia and abnormal PDGFRA/B featured by distinct hematologic and clinical manifestations.

Resistant mechanism about rapamycin and solution / 国际肿瘤学杂志

mTOR signaling pathway is closely related to cell proliferation,cell cycle and other pathological processes about tumor.Rapamycin plays an anti-tumor effect through inhibiting mTOR,but it prone to drug resistance,which leads to limited clinical application.Its resistant mechanism is related with the activation of PI3K-Akt,which is regulated with negative feedback.Dual inhibitors of related proteins of mTOR pathway are expected to reverse the drug resistance.

Comparative study on the efficacy of Hyper CVAD/MA regimen and CHOP or CHOP like regimen in the treatment of primary peripheral T cell lymphoma / 中华血液学杂志

<p><b>OBJECTIVE</b>To evaluate the curative efficacy and safety of two regimens, Hyper CVAD/MA and CHOP/CHOP, in the treatment of primary peripheral T cell lymphoma (PTCL).</p><p><b>METHODS</b>The clinical data of 80 primary PTCL patients were retrospectively analyzed, and the efficacy and safety of the two regimens, Hyper CVAD/MA and CHOP/CHOP, were evaluated.</p><p><b>RESULTS</b>Of 80 patients with primary PTCL, 23 were treated with Hyper CVAD/MA regimen (HM group, experimental group) and 57 with CHOP or CHOP-like regimen (CC group, control group). The differences between overall response rate (ORR) among HM group and CC group (78.3% vs 54.4%, P = 0.047), ORR in patients with IPI score of 0-2 (86.7% vs 55.2%, P = 0.037), courses of chemotherapy to achieve remission (4 vs 6, P = 0.004), median progression-free survival (PFS) time (24 months vs 12 months, P = 0.039) and 1- year PFS rate (82.6% against 45.6%, P = 0.006) were statistically significant. The relapse rates were similar between 2 groups (50.0% vs 54.8%, P = 0.744). The 2-year and 3-year progression-free survivals and 3 year overall survival were not significantly different (P > 0.05). Patients in Hyper CVAD/MA group are more susceptible to neutropenia (<1.5 × 10⁹/L) (73.9% vs 38.6%, P=0.004).</p><p><b>CONCLUSION</b>The curative effect of Hyper CVAD/MA regimen as induction therapy in treatment of PTCL patients except ALK positive PTCL patients was better than that of CHOP/CHOP-like regimen.</p>